A Phase I Study Of Xl647, An Egfr, Her2, Vegfr2 Inhibitor, Administered Orally Daily To Patients (Pts) With Advanced Solid Malignancies (Asm)Heather A. Wakelee, J. M. Fehling,Julian R. Molina, Janet Lensing,Roel P. Funke,Dale Miles,B. I. SikicJOURNAL OF CLINICAL ONCOLOGY（2008）引用 21|浏览6暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
